Core Insights - The article emphasizes the importance of combining top-down macro analysis with bottom-up stock selection to identify mispriced investment opportunities in the market [1]. Group 1: Investment Strategy - The company employs a multi-asset strategy and equity portfolio management approach, focusing on earnings, technological disruption, policy shifts, and capital flows [1]. - The analysis aims to deliver high-conviction ideas and contrarian views, providing deep breakdowns of both growth and value stocks [1]. Group 2: Market Positioning - The company utilizes real-time positioning tools, including Bloomberg and various models and data, to enhance investment decisions [1]. - The focus is on identifying potential investment opportunities before the market recognizes them, highlighting a proactive investment approach [1].

TORONTO, ON / ACCESS Newswire / October 27, 2025 / Lahontan Gold Corp. (TSXV:LG)(OTCQB:LGCXF) (the "Company" or "Lahontan") is pleased to announce the receipt of Cdn $4,316,948 from the exercise of warrants and stock options during the period July 4 through October 23, 2025. Following the exercise of the warrants, stock options, and the issuance of shares associated with the purchase of the York unpatented mining claims at the Santa Fe Mine Project (please see press release dated October 23, 2025), the Comp ...

Group 1 - Gold Royalty Corp. will present at the Red Cloud Fall Mining Showcase 2025, inviting shareholders and interested parties to learn about the company's latest developments [1][2] - The annual conference will take place in-person at the Sheraton Centre Toronto Hotel on November 4 & 5, 2025, featuring presentations from industry leaders [2] - John Griffith, Chief Development Officer of Gold Royalty, is scheduled to present on November 4th at 11:20 am Eastern Standard Time [2] Group 2 - Gold Royalty Corp. focuses on providing creative financing solutions to the metals and mining industry, aiming to invest in high-quality, sustainable mining operations [3] - The company has a diversified portfolio of over 250 royalties located in mining-friendly jurisdictions throughout the Americas, which offers lower risk exposure to gold [3] - The mission of Gold Royalty is to generate superior long-term returns for shareholders through its royalty and streaming interests [3]

Accessibility StatementSkip Navigation Building on 12-week findings, icotrokinra demonstrated clinically meaningful outcomes at Week 28 with 31.7% of patients achieving clinical remission and 38.1% showing endoscopic improvement versus placebo in the Phase 2b ANTHEM-UC study Results support Phase 3 clinical development of icotrokinra, a first-in-class targeted oral peptide that precisely blocks the IL-23 receptor, in both moderately to severely active ulcerative colitis and Crohn's disease PHOENIX, Oct. 27, ...

Toronto, Ontario--(Newsfile Corp. - October 27, 2025) - NorthStar Gaming Holdings Inc. (TSXV: BET) (OTCQB: NSBBF) ("NorthStar" or the "Company") announces that it has launched a new website called "The Boost." Available at www.theboostbet.ca. The Boost will feature original casino and sports betting content designed for Canadian gaming enthusiasts.The Boost will leverage the sports betting and casino content currently produced for the Company's premium online betting platform, NorthStar Bets. NorthStar exp ...

Core Insights - BioRestorative Therapies, Inc. has achieved a significant intellectual property milestone with the Japanese Patent Office issuing a Notice of Allowance for its ThermoStem platform, which focuses on stem cell-based therapies for obesity and metabolic disorders [1][2] Company Developments - The newly allowed patent provides broad protection for BioRestorative's allogeneic, off-the-shelf brown adipose-derived stem cell (BADSC) technology, covering therapeutic cells and various methods of encapsulation and delivery [2] - This patent strengthens BioRestorative's position in developing next-generation, cell-based alternatives to GLP-1 drugs, which are rapidly growing in the therapeutic market [3][4] - The CEO of BioRestorative highlighted that the patent allowance validates the progress made with ThermoStem and positions the company favorably in the commercial landscape, especially as discussions with potential strategic partners continue [4] Market Context - The global obesity market is projected to exceed $100 billion annually by the end of the decade, driven by demand for GLP-1 therapies, which BioRestorative aims to address with its ThermoStem platform [4] - BioRestorative's ThermoStem platform is designed to provide an alternative to chronic GLP-1 injections, mitigate muscle loss, and reduce cardiovascular risks associated with current therapies [6] Clinical Programs - BioRestorative is developing two core clinical programs: - The Disc/Spine Program (brtxDISC) focuses on a cell therapy candidate, BRTX-100, for treating lumbosacral disc disorders and has commenced a Phase 2 clinical trial [5] - The Metabolic Program (ThermoStem) targets obesity and metabolic disorders using BADSC to generate brown adipose tissue, with initial preclinical research indicating potential benefits in caloric burning and metabolic regulation [6][7] Commercial Initiatives - BioRestorative operates a BioCosmeceutical platform, offering a cell-based secretome product aimed at cosmetic applications, with plans to expand its offerings in the aesthetic product space [8]

Standard Uranium Announces Filing of NI 43-101 Technical Report on the Corvo Uranium Project, Northern SaskatchewanOctober 27, 2025 7:30 AM EDT | Source: Standard Uranium Ltd.Vancouver, British Columbia--(Newsfile Corp. - October 27, 2025) - Standard Uranium Ltd. (TSXV: STND) (OTCQB: STTDF) (FSE: 9SU0) ("Standard Uranium" or the "Company") is pleased to announce it has filed a technical report (the "Report") entitled "Technical Report on the Corvo Property - Northeastern Saskatchewan, Canada" ...

Core Viewpoint - Intellia Therapeutics has temporarily paused patient dosing and screening for its Phase 3 clinical trials of nex-z due to safety concerns following a serious adverse event in a trial participant [1][2][3] Company Actions - The company is consulting with experts and regulatory authorities to develop a strategy for resuming enrollment in the MAGNITUDE and MAGNITUDE-2 trials [2][3] - As of now, over 650 patients with ATTR-CM are enrolled in the MAGNITUDE trial, and 47 patients with ATTR-PN are enrolled in the MAGNITUDE-2 trial, with more than 450 patients estimated to have been dosed with nex-z [3] Product Information - Nex-z is based on CRISPR/Cas9 gene editing technology and aims to be the first one-time treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and/or polyneuropathy (ATTR-PN) [5] - The drug is designed to inactivate the TTR gene and has shown promising interim Phase 1 clinical data indicating consistent and long-lasting TTR reduction [5] Regulatory Status - Nex-z has received Orphan Drug and RMAT Designation from the FDA and Orphan Drug Designation from the European Commission [5]

Core Viewpoint - Telesat is set to announce its financial results for the three and nine month periods ending September 30, 2025, during a conference call scheduled for November 4, 2025, at 10:30 a.m. EST [1] Group 1: Financial Results Announcement - A news release containing Telesat's financial results will be posted on its website prior to the conference call [2] - The conference call will be accessible via a toll-free dial-in number and an international number for callers outside North America [2] - A replay of the teleconference will be available for a limited time after the call [3] Group 2: Company Overview - Telesat is recognized as one of the largest and most successful global satellite operators, known for its engineering excellence and customer service [4] - The company is focused on delivering critical connectivity solutions to address complex communication challenges, enhancing operations and driving growth for its customers [4] Group 3: Innovation and Future Connectivity - Telesat Lightspeed, the company's advanced Low Earth Orbit (LEO) satellite network, aims to meet future connectivity demands with high-capacity, secure, and resilient links [5] - The network is designed to provide fibre-like speeds and is tailored for telecom, government, maritime, and aeronautical customers [5]

Follow-on draw affirms investor support for Capstone's growth strategy and reflects the company's disciplined approach to financing accretive acquisitions. NEW YORK, NY / ACCESS Newswire / October 27, 2025 / Capstone Holding Corp. (NASDAQ:CAPS), a national building products distribution platform, today announced a $3.25 million draw from its existing convertible note facility. ...